Neuropeutics Receives the Inaugural AbbVie Biotech Innovators Award

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

AbbVie, in partnership with the University of Toronto’s SpinUp, recently announced Neuropeutics Inc as the recipient of the AbbVie Biotech Innovators Award, a national prize to help foster innovation and support growth in Canada’s life sciences sector. Following a competitive selection process, the award, funded by AbbVie, has been granted to Neuropeutics Inc for developing small molecules preventing and reversing protein aggregation as therapeutics for neurodegenerative diseases.

Neuropeutics presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

ProteinQure Secures Series A to Advance First AI-Designed Peptide Therapeutic into Clinical Trials
Next

JN Nova Pharma Secures Health Canada Approval for Phase I Trial of its Long COVID Therapy